JP2025084856A5 - - Google Patents
Info
- Publication number
- JP2025084856A5 JP2025084856A5 JP2025029906A JP2025029906A JP2025084856A5 JP 2025084856 A5 JP2025084856 A5 JP 2025084856A5 JP 2025029906 A JP2025029906 A JP 2025029906A JP 2025029906 A JP2025029906 A JP 2025029906A JP 2025084856 A5 JP2025084856 A5 JP 2025084856A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- forming
- acid
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361833196P | 2013-06-10 | 2013-06-10 | |
| US61/833,196 | 2013-06-10 | ||
| JP2020084989A JP6891322B2 (ja) | 2013-06-10 | 2020-05-14 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2021087378A JP7263439B2 (ja) | 2013-06-10 | 2021-05-25 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2023064715A JP2023089126A (ja) | 2013-06-10 | 2023-04-12 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023064715A Division JP2023089126A (ja) | 2013-06-10 | 2023-04-12 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025084856A JP2025084856A (ja) | 2025-06-03 |
| JP2025084856A5 true JP2025084856A5 (https=) | 2025-08-08 |
Family
ID=51063849
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519576A Active JP6998655B2 (ja) | 2013-06-10 | 2014-06-09 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2020084989A Active JP6891322B2 (ja) | 2013-06-10 | 2020-05-14 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2021087378A Active JP7263439B2 (ja) | 2013-06-10 | 2021-05-25 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2023064715A Pending JP2023089126A (ja) | 2013-06-10 | 2023-04-12 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2025029906A Pending JP2025084856A (ja) | 2013-06-10 | 2025-02-27 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519576A Active JP6998655B2 (ja) | 2013-06-10 | 2014-06-09 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2020084989A Active JP6891322B2 (ja) | 2013-06-10 | 2020-05-14 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2021087378A Active JP7263439B2 (ja) | 2013-06-10 | 2021-05-25 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2023064715A Pending JP2023089126A (ja) | 2013-06-10 | 2023-04-12 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| HRP20220718T1 (hr) | 2013-11-11 | 2022-09-30 | Amgen Inc. | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| IL308399B2 (en) * | 2018-04-30 | 2025-08-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| CN112804994A (zh) * | 2018-05-25 | 2021-05-14 | 卡托斯医疗公司 | 治疗骨髓增殖性肿瘤的方法 |
| IL315550A (en) | 2018-08-31 | 2024-11-01 | Amgen Inc | A process for preparing an MDM2 inhibitor |
| CN110963958B (zh) | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| US20230272001A1 (en) * | 2020-05-22 | 2023-08-31 | Merck Sharp & Dohme Llc | Novel processes for preparing conjugates of the il-2 protein |
| CA3181715A1 (en) | 2020-08-27 | 2022-03-03 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| US12054449B2 (en) | 2021-08-05 | 2024-08-06 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate crystalline form and method for manufacturing the same |
| EP4382509A4 (en) * | 2021-08-05 | 2025-08-27 | Bio Pharm Solutions Co Ltd | CRYSTALLINE FORM OF PHENYLCARBAMATE AND PROCESS FOR ITS PREPARATION |
| WO2023039161A1 (en) * | 2021-09-09 | 2023-03-16 | Kartos Therapeutics | Methods of treating cancer dependent on myc gene expresssion |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN115925589A (zh) * | 2022-12-26 | 2023-04-07 | 诚达药业股份有限公司 | 一种脂肪族亚磺酸钙盐及其制备方法 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2483213A (en) * | 1947-06-14 | 1949-09-27 | American Cyanamid Co | Alpha naphthalene sulfonic anhydride |
| CH436295A (de) | 1961-11-13 | 1967-05-31 | Mcneilab Inc | Verfahren zur Herstellung neuer 3-Morpholinone |
| US3518236A (en) * | 1967-07-20 | 1970-06-30 | Uniroyal Inc | Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JP2604472B2 (ja) | 1989-07-12 | 1997-04-30 | 株式会社クラレ | 重合性組成物 |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| CA2195677C (en) | 1994-08-19 | 2005-11-08 | Martin Winn | Endothelin antagonists |
| ES2259803T3 (es) | 1996-02-13 | 2006-10-16 | Abbott Laboratories | Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina. |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| NZ502395A (en) | 1997-08-04 | 2002-08-28 | Abbott Lab | 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists |
| WO1999031507A1 (en) | 1997-12-18 | 1999-06-24 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US7214540B2 (en) * | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
| US6630006B2 (en) * | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
| US7195670B2 (en) * | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
| US7052545B2 (en) * | 2001-04-06 | 2006-05-30 | California Institute Of Technology | High throughput screening of crystallization of materials |
| DE19951418A1 (de) * | 1999-10-26 | 2001-05-03 | Merck Patent Gmbh | Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| AU2002228598A1 (en) * | 2000-11-20 | 2002-06-03 | Parallel Synthesis Technologies, Inc. | Methods and devices for high throughput crystallization |
| HUP0304058A2 (hu) | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| CA2446380A1 (en) | 2001-05-08 | 2002-11-14 | Yale University | Proteomimetic compounds and methods |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| BR0215157A (pt) | 2001-12-18 | 2004-10-19 | Hoffmann La Roche | Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores |
| US6860940B2 (en) * | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
| US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| BRPI0511328A (pt) | 2004-05-18 | 2007-12-04 | Hoffmann La Roche | cis-imidazolinas |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| JP2007297283A (ja) * | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| EA012181B1 (ru) | 2004-10-18 | 2009-08-28 | Амген, Инк. | Соединения тиадиазола и их применение |
| CN102372704B (zh) | 2005-02-18 | 2014-10-08 | 田边三菱制药株式会社 | 脯氨酸衍生物的盐，其溶剂合物，及其生产方法 |
| JP4955646B2 (ja) | 2005-03-16 | 2012-06-20 | エフ．ホフマン−ラ ロシュ アーゲー | シス−２，４，５−トリアリール−イミダゾリン及びそれらの抗癌薬としての使用 |
| US20060270709A1 (en) | 2005-04-04 | 2006-11-30 | Eisai Co. Ltd. | Dihydropyridine compounds and compositions for headaches |
| JP5284779B2 (ja) * | 2005-06-07 | 2013-09-11 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | コンジュゲート化された向精神薬の新規な塩およびその調製方法 |
| WO2007015929A2 (en) * | 2005-07-27 | 2007-02-08 | University Of Toledo | Epothilone analogues |
| CN101316823B (zh) | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| MY149143A (en) | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
| EP2046328A4 (en) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| WO2008118454A2 (en) | 2007-03-23 | 2008-10-02 | Amgen Inc. | Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer |
| RS53151B (sr) | 2007-03-23 | 2014-06-30 | Amgen Inc. | 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k) |
| EA017389B1 (ru) | 2007-03-23 | 2012-12-28 | Амген Инк. | Гетероциклические соединения и их применение |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| CN101809002B (zh) | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| AU2008282728B2 (en) | 2007-08-02 | 2012-04-19 | Amgen Inc. | Pl3 kinase modulators and methods of use |
| MX2010003868A (es) | 2007-10-09 | 2010-04-27 | Hoffmann La Roche | Cis-imidazolinas quirales. |
| AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US20100256191A1 (en) | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| CA2718959A1 (en) | 2008-03-21 | 2009-09-24 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| WO2010030704A2 (en) * | 2008-09-10 | 2010-03-18 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| AU2009294673B2 (en) | 2008-09-18 | 2014-08-14 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| WO2010083246A1 (en) | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| AU2010216239B2 (en) | 2009-02-18 | 2012-06-14 | Amgen Inc. | Indole/benzimidazole compounds as mTOR kinase inhibitors |
| MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| MX2011012037A (es) | 2009-05-13 | 2012-02-28 | Amgen Inc | Compuestos de heteroarilo como inhibidores de pikk. |
| EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
| CN102625799A (zh) | 2009-06-25 | 2012-08-01 | 安姆根有限公司 | 杂环化合物及其用途 |
| WO2010151735A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| EP2445902A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | Heterocyclic compounds and their uses as inhibitors of pi3k activity |
| WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| EP2486044A2 (en) * | 2009-10-09 | 2012-08-15 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| EP2534667A2 (en) * | 2010-02-10 | 2012-12-19 | Mochii, Inc. (d/b/a Voxa) | Aberration-correcting dark-field electron microscopy |
| IT1399923B1 (it) * | 2010-05-11 | 2013-05-09 | Cbb Net S A | Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| TWI674262B (zh) * | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| KR101921102B1 (ko) * | 2011-04-28 | 2018-11-22 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 아조디카본아미드의 신규 제조법 |
| TW201309651A (zh) * | 2011-06-29 | 2013-03-01 | Otsuka Pharma Co Ltd | 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法 |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| CN103373951B (zh) * | 2012-04-28 | 2016-03-09 | 上海医药工业研究院 | 一种拉帕替尼中间体的制备方法 |
| US20160002185A1 (en) | 2013-02-19 | 2016-01-07 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
-
2014
- 2014-06-09 CN CN201480033215.1A patent/CN105358530A/zh active Pending
- 2014-06-09 SG SG10201801402XA patent/SG10201801402XA/en unknown
- 2014-06-09 KR KR1020157036194A patent/KR20160018576A/ko not_active Ceased
- 2014-06-09 CA CA2914723A patent/CA2914723C/en active Active
- 2014-06-09 BR BR122020003153-0A patent/BR122020003153B1/pt active IP Right Grant
- 2014-06-09 CA CA3200532A patent/CA3200532A1/en active Pending
- 2014-06-09 EA EA202091612A patent/EA202091612A1/ru unknown
- 2014-06-09 ES ES14735785T patent/ES2851023T3/es active Active
- 2014-06-09 WO PCT/US2014/041594 patent/WO2014200937A1/en not_active Ceased
- 2014-06-09 IL IL297860A patent/IL297860A/en unknown
- 2014-06-09 TN TN2015000521A patent/TN2015000521A1/en unknown
- 2014-06-09 HR HRP20202065TT patent/HRP20202065T1/hr unknown
- 2014-06-09 MX MX2015016856A patent/MX2015016856A/es unknown
- 2014-06-09 MA MA38714A patent/MA38714A1/fr unknown
- 2014-06-09 MA MA53572A patent/MA53572A1/fr unknown
- 2014-06-09 DK DK14735785.9T patent/DK3008039T3/da active
- 2014-06-09 SI SI201431735T patent/SI3008039T1/sl unknown
- 2014-06-09 AP AP2015008891A patent/AP2015008891A0/xx unknown
- 2014-06-09 MY MYPI2019006678A patent/MY205257A/en unknown
- 2014-06-09 PT PT147357859T patent/PT3008039T/pt unknown
- 2014-06-09 EA EA201891642A patent/EA201891642A1/ru unknown
- 2014-06-09 CA CA3201958A patent/CA3201958A1/en active Pending
- 2014-06-09 UA UAA202000229A patent/UA129695C2/uk unknown
- 2014-06-09 PL PL14735785T patent/PL3008039T3/pl unknown
- 2014-06-09 UA UAA201600159A patent/UA121301C2/uk unknown
- 2014-06-09 BR BR112015031004-4A patent/BR112015031004B1/pt active IP Right Grant
- 2014-06-09 PH PH1/2020/550916A patent/PH12020550916A1/en unknown
- 2014-06-09 MX MX2019012007A patent/MX379872B/es unknown
- 2014-06-09 CN CN201811222652.4A patent/CN110003092A/zh active Pending
- 2014-06-09 EP EP20197741.0A patent/EP3805232B1/en active Active
- 2014-06-09 CA CA3115609A patent/CA3115609C/en active Active
- 2014-06-09 KR KR1020237002549A patent/KR20230019216A/ko not_active Ceased
- 2014-06-09 MY MYPI2015002896A patent/MY194848A/en unknown
- 2014-06-09 PE PE2015002561A patent/PE20160113A1/es unknown
- 2014-06-09 SM SM20210013T patent/SMT202100013T1/it unknown
- 2014-06-09 LT LTEP14735785.9T patent/LT3008039T/lt unknown
- 2014-06-09 PE PE2020000392A patent/PE20210153A1/es unknown
- 2014-06-09 RS RS20201515A patent/RS61192B1/sr unknown
- 2014-06-09 CN CN201910783352.1A patent/CN110627708A/zh active Pending
- 2014-06-09 EA EA201592305A patent/EA031254B1/ru unknown
- 2014-06-09 CR CR20210290A patent/CR20210290A/es unknown
- 2014-06-09 SG SG11201509896VA patent/SG11201509896VA/en unknown
- 2014-06-09 AU AU2014278428A patent/AU2014278428B2/en active Active
- 2014-06-09 EP EP14735785.9A patent/EP3008039B1/en active Active
- 2014-06-09 NZ NZ714821A patent/NZ714821A/en unknown
- 2014-06-09 JP JP2016519576A patent/JP6998655B2/ja active Active
- 2014-06-09 HU HUE14735785A patent/HUE053047T2/hu unknown
- 2014-06-09 KR KR1020247035781A patent/KR20240159641A/ko active Pending
- 2014-06-09 KR KR1020217030265A patent/KR20210121270A/ko not_active Ceased
- 2014-06-10 TW TW109118829A patent/TWI791153B/zh active
- 2014-06-10 AR ARP140102235A patent/AR096582A1/es not_active Application Discontinuation
- 2014-06-10 US US14/301,087 patent/US9376386B2/en active Active
- 2014-06-10 TW TW107134691A patent/TWI698428B/zh active
- 2014-06-10 JO JOP/2014/0186A patent/JO3768B1/ar active
- 2014-06-10 UY UY0001035605A patent/UY35605A/es not_active Application Discontinuation
- 2014-06-10 TW TW103120104A patent/TWI649306B/zh active
- 2014-06-10 UY UY0001040179A patent/UY40179A/es not_active Application Discontinuation
-
2015
- 2015-11-16 IL IL242622A patent/IL242622B/en active IP Right Grant
- 2015-12-03 PH PH12015502705A patent/PH12015502705B1/en unknown
- 2015-12-10 CL CL2015003589A patent/CL2015003589A1/es unknown
- 2015-12-23 MA MA43288A patent/MA43288B1/fr unknown
-
2016
- 2016-01-07 CR CR20160010A patent/CR20160010A/es unknown
- 2016-05-24 US US15/163,186 patent/US9855259B2/en active Active
- 2016-06-07 US US15/175,798 patent/US20160287570A1/en not_active Abandoned
- 2016-06-07 US US15/175,821 patent/US9757367B2/en active Active
- 2016-06-07 US US15/175,805 patent/US9623018B2/en active Active
- 2016-06-07 US US15/175,824 patent/US9801867B2/en active Active
-
2017
- 2017-11-22 US US15/820,830 patent/US20180092898A1/en not_active Abandoned
-
2018
- 2018-11-07 AU AU2018260844A patent/AU2018260844B2/en active Active
-
2019
- 2019-01-08 CL CL2019000056A patent/CL2019000056A1/es unknown
- 2019-05-07 IL IL266504A patent/IL266504B/en active IP Right Grant
- 2019-10-25 US US16/664,103 patent/US20200281912A1/en not_active Abandoned
-
2020
- 2020-04-28 AR ARP200101191A patent/AR119727A2/es active IP Right Grant
- 2020-05-14 JP JP2020084989A patent/JP6891322B2/ja active Active
- 2020-11-10 AU AU2020267169A patent/AU2020267169B2/en active Active
- 2020-11-22 JO JOP/2020/0296A patent/JOP20200296A1/ar unknown
- 2020-12-18 CY CY20201101201T patent/CY1123661T1/el unknown
-
2021
- 2021-03-08 CL CL2021000566A patent/CL2021000566A1/es unknown
- 2021-03-25 IL IL281807A patent/IL281807B2/en unknown
- 2021-05-25 JP JP2021087378A patent/JP7263439B2/ja active Active
- 2021-10-13 US US17/500,039 patent/US20220280496A1/en not_active Abandoned
-
2022
- 2022-11-16 AU AU2022271425A patent/AU2022271425B2/en active Active
-
2023
- 2023-04-12 JP JP2023064715A patent/JP2023089126A/ja active Pending
- 2023-05-08 US US18/313,428 patent/US20230301974A1/en not_active Abandoned
-
2024
- 2024-06-03 AR ARP240101415A patent/AR132854A2/es unknown
- 2024-09-02 AU AU2024216533A patent/AU2024216533A1/en active Pending
-
2025
- 2025-02-27 JP JP2025029906A patent/JP2025084856A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025084856A5 (https=) | ||
| JP5752256B2 (ja) | ２−メトキシメチル−１，４−ベンゼンジアミンの製造方法 | |
| JP2017520547A5 (https=) | ||
| JP2020097607A (ja) | クロマノン誘導体の新規な製造方法 | |
| JP2011046751A (ja) | ヒンバシンアナログの合成 | |
| JP2020525447A5 (https=) | ||
| WO2010004957A1 (ja) | キラルなイリジウムアクア錯体およびそれを用いた光学活性ヒドロキシ化合物の製造方法 | |
| JP2010043053A (ja) | 高純度のレバミピドの製造方法 | |
| JP2008539163A (ja) | ヒドラゾン類の製造法 | |
| JP5039419B2 (ja) | クロスカップリング化合物の製造方法 | |
| TW201326116A (zh) | ２，６－二乙基－４－甲基苯醋酸之製造方法 | |
| JP6124015B2 (ja) | ペンタフルオロスルファニル安息香酸の製造方法 | |
| JP2024096941A5 (https=) | ||
| CN100516022C (zh) | 高纯度烯胺类的制备方法 | |
| JP4023255B2 (ja) | ジカルボン酸の製造方法とそれに用いる触媒の製造方法 | |
| JP3817478B2 (ja) | ３，３−ジフェニル−２，３−エポキシプロピオン酸エステルのエナンチオ選択的製造方法 | |
| JP2008517967A5 (https=) | ||
| JPH06771B2 (ja) | オキセタン−３−カルボン酸の製法 | |
| US6403817B1 (en) | Method for preparing prostaglandin E-type compound | |
| JPS6254416B2 (https=) | ||
| JP2006124325A (ja) | ｄｌ−１，２−ジフェニルエチレンジアミンの製造方法 | |
| JP2005289988A (ja) | アミノ化合物の製造法 | |
| WO2001096273A1 (en) | Process for the preparation of 1-substituted-cyclo-hexanecarbonyl halides | |
| CN121064191A (zh) | 一种奥格列龙半钙盐水合物的制备方法 | |
| TW565564B (en) | Process for the production of N-phosphonomethylglycine |